Amsterdam Molecular Therapeutics Reports Half Year Re...( The net loss for the first six months...)

The net loss for the first six months was EUR 8.1 million, as compared to a net loss of EUR 8.6 million in the same period of 2007.

At June 30, 2008, AMT's cash and cash equivalents amounted to EUR 43.1 million, compared to EUR 51.3 million at December 31, 2007.

"AMT had an excellent first half of 2008. During the first half of this year AMT has made substantial progress in the development of our lead product, in strengthening our pipeline, and in our business and corporate development. All of this reinforces our position as a leader in gene therapy and gives us a strong foundation for further growth," said Ronald Lorijn, CEO of AMT.

Conference call and webcast presentation

AMT will conduct a conference call open to the public today at 2.00 p.m. CET, which will also be webcast. Netherlands Dial In: +31(0)800-949-4517 (toll free); US Dial In: +1-866-291-4166 (toll free); UK Dial In: +44-207-107-0611. The webcast can be accessed via AMT's website at http://www.amtbiopharma.com. Please go to the website 15 minutes prior to the call to register, download and install the necessary audio software. Playback of the call will be availably for 24 hours after the call. Dial In: +41-91-612-4330; +44-20-7108-6233; or +1-866-416-2558. The archived webcast also will be available for replay shortly after the close of the call.

About Amsterdam Molecular Therapeutics

AMT has a unique gene therapy platform that to date appears to circumvent many if not all of the obstacles that have prevented gene therapy from becoming a mainstay of clinical medicine. Using adeno-associated viral (AAV) vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV production platform. As such, AMT's proprietary platform holds tremendous promise for thousands of rare (orphan) diseases, especially the on
'/>"/>